UBS analyst David Dai lowered the price target on Syndax Pharmaceuticals (NASDAQ: SNDX) to $35.00 (from $37.00) while maintaining a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE